Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Catholic Kwandong University | OTHER |
Not provided
Not provided
Not provided
Not provided
Evaluate the efficacy and safety of Chuna treatment as an adjunctive therapy in patients with moderate pain following total knee replacement.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chuna + Usual care | Experimental |
| |
| Usual care | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chuna + Usual care(Celecoxib and esomeprazole) | Procedure | Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp). CT and UC group will receive the same UC regimen. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline K-WOMAC score at week 4 | Assess the recovery of knee function | Week 0, Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline K-WOMAC score at every visit | Assess the recovery of knee function | Week 0, Week 2, Week 4, Week 8 |
| Change from baseline EQ-5D score at every visit | EQ-5D is a tool developed for health-related quality of life (HRQoL) assessment, and is widely used in the health care sector. Scores range from -1, 'health worse than death' to 1, 'perfect health'. EQ-5D-5L has 5 dimensions covering current health status and functionality: mobility (M), self care (SC), usual activities (UA), pain/discomfort (PD), and anxiety/depression (AD), to be rated out of 5 grades (1, no problem; 2, slight problem; 3, some/moderate problem; 4, severe problem; 5, extreme problem). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yun Kyung Song, PhD | Gachon university of Gil oriental hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Catholic Kwandong University International St. Mary'S Hospita | Incheon | 22711 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Usual care(Celecoxib and esomeprazole) | Drug | Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp). |
|
| Week 0, Week 2, Week 4, Week 8 |
| Change from baseline Numeric rating scale score at every visit | In pain measurement using NRS, patients are asked to rate their pain by selecting a number from 0 to 10 that best represents their pain severity between the anchors of 0 which indicates 'no pain', and 10 which indicates 'worst pain possible'. | Week 0, Week 2, Week 4, Week 8 |
| Change from baseline in Physical Condition related with mobility at every visit | mobility (5 meters walking test at comfortable speed - 5mWT) (meters/second) | Week 0, Week 2, Week 4, Week 8, Week 12 |
| Change from baseline in Physical Condition related with endurance at every visit | endurance (Sit-to-stand test - STS) (seconds) | Week 0, Week 2, Week 4, Week 8, Week 12 |
| Change from baseline in Timed Up and Go Test at every visit | a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value >12 seconds). | Week 0, Week 2, Week 4, Week 8, Week 12 |
| Change from baseline in Alternative-Step Test at every visit | a functional test measuring clinical balance performance, and it has been shown to predict fall risk among elderly subjects (seconds) | Week 0, Week 2, Week 4, Week 8, Week 12 |
| Change from baseline in Range of motion score at every visit | Compare flexion and extension angle using long arm goniometer between experimental and comparator group | Week 0, Week 2, Week 4, Week 8 |
| Difference between the EuroQol Visual Analogue Scale (EQ-VAS) at each timepoint and baseline, respectively | EQ-VAS uses a vertical 10cm line labeled at each end with scale anchors. EQ-VAS is used to indicate the patient's health state and patients are asked to mark a point that represents their health state between the anchors of 'worst health state' and 'best health state imaginable'. Scores are recorded in millimeters with a total range of 0-100 millimeters. | Week 0, Week 2, Week 4, Week 8 |
| Cost per QALY(Quality Adjusted Life Years) gained | The quality of life estimation for QALY calculation will use the quality of life derived from EQ-5D as the main evaluation variable, and the calculation method is using Area under the curve method | Week 0, Week 4, Week 8, Week 12 |
| ID | Term |
|---|---|
| D064098 | Esomeprazole |
| ID | Term |
|---|---|
| D009853 | Omeprazole |
| D053799 | 2-Pyridinylmethylsulfinylbenzimidazoles |
| D013454 | Sulfoxides |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided